Health Science Center, Yangtze University, Jingzhou, China.
Department of Dermatology, Jingzhou Hospital, Yangtze University, Candidate Branch of National Clinical Research Center for Skin and Immune Diseases, Jingzhou, China.
Front Cell Infect Microbiol. 2022 Apr 14;12:864912. doi: 10.3389/fcimb.2022.864912. eCollection 2022.
and infections in humans are generally chronic and stubborn. The use of azoles alone cannot usually inhibit the growth of these fungi. To further explore the combined effect of multiple drugs and potential mechanisms of action, we tested the antifungal effects of tacrolimus (FK506) and everolimus in combination with azoles and on 15 clinical strains of / species and detected the level of Rhodamine 6G, ROS activity, and apoptosis. The results showed that the combinations of tacrolimus with itraconazole, voriconazole, and posaconazole showed synergistic effects on 9 strains (60%), 10 strains (73%), and 7 strains (47%), respectively, and the combinations of everolimus with itraconazole, voriconazole, and posaconazole showed synergistic effects on 8 strains (53%), 8 strains (53%), and 7 strains (47%), respectively. The synergistic effects might correspond to the elevated ROS activity (the tacrolimus + itraconazole group compared to the itraconazole group, ( < 0.05)), early apoptosis (itraconazole ( < 0.05) and voriconazole ( < 0.05) combined with everolimus), and late apoptosis (the tacrolimus + itraconazole group compared to the itraconazole group, ( < 0.01); the tacrolimus + posaconazole group compared to the posaconazole group, ( < 0.05)), but not inhibition of efflux pump activity. Our results suggested that a combination of tacrolimus or everolimus and azoles have a synergistic effect against . The synergistic mechanisms of action might be triggering excessive ROS activity and apoptosis, the survival rate of (sixth instar larvae) was significantly improved by tacrolimus alone, everolimus alone, azoles alone, and tacrolimus and everolimus combined with azoles separately ( < 0.05 for the tacrolimus group; < 0.01 for the everolimus group and the itraconazole group; = 0.0001 for the tacrolimus and posaconazole group; < 0.0001 for other groups except the everolimus and itraconazole group, everolimus and posaconazole group, and tacrolimus and itraconazole group). From the results, we infer that the combination of tacrolimus or everolimus with azoles has obvious synergistic effect on , and might enhance the level of apoptosis and necrosis. However, the synergistic effects were not related to the efflux pump. In conclusion, from our and study, tacrolimus and everolimus combined with azoles may have a synergistic effect in the treatment against , improving the drug activity of azoles and promoting a better prognosis for patients.
并且真菌感染通常是慢性和顽固的。单独使用唑类药物通常不能抑制这些真菌的生长。为了进一步探索多种药物的联合作用和潜在的作用机制,我们测试了他克莫司(FK506)和依维莫司与唑类药物联合使用对 15 株临床分离株/种的抗真菌作用,并检测了罗丹明 6G、ROS 活性和细胞凋亡。结果表明,他克莫司与伊曲康唑、伏立康唑和泊沙康唑联合使用对 9 株(60%)、10 株(73%)和 7 株(47%)菌株表现出协同作用,依维莫司与伊曲康唑、伏立康唑和泊沙康唑联合使用对 8 株(53%)、8 株(53%)和 7 株(47%)菌株表现出协同作用。协同作用可能与 ROS 活性升高相对应(他克莫司+伊曲康唑组与伊曲康唑组相比,(<0.05)),早期凋亡(伊曲康唑(<0.05)和伏立康唑(<0.05)联合依维莫司)和晚期凋亡(他克莫司+伊曲康唑组与伊曲康唑组相比,(<0.01);他克莫司+泊沙康唑组与泊沙康唑组相比,(<0.05)),但不抑制外排泵活性。我们的结果表明,他克莫司或依维莫司与唑类药物联合使用对具有协同作用。作用机制可能是触发过度的 ROS 活性和细胞凋亡,他克莫司单独、依维莫司单独、唑类药物单独以及他克莫司和依维莫司联合唑类药物分别显著提高(第六龄幼虫)的存活率(他克莫司组(<0.05);依维莫司组和伊曲康唑组(<0.01);他克莫司和泊沙康唑组(=0.0001);其他组除外依维莫司和伊曲康唑组、依维莫司和泊沙康唑组以及他克莫司和伊曲康唑组)。从结果推断,他克莫司或依维莫司与唑类药物联合使用对具有明显的协同作用,可能增强细胞凋亡和坏死的水平。然而,协同作用与外排泵无关。总之,从我们的和研究中可以看出,他克莫司和依维莫司联合唑类药物可能在治疗方面具有协同作用,提高唑类药物的活性,改善患者预后。